Chinese molecular diagnostics startup Singleron Biotechnologies has closed a $30 million Series A2 round of
funding solely from existing investors, according to a company statement on last Thursday.
It brings the total corpus raised by Singleron in the past four months to $70 million. In November 2020, it pocketed
more than $10 million in a Series A+ round. Singleron had also garnered $30 million in a Series A funding led by
Chinese biomedical venture capital firm Lilly Asia Ventures (LAV) in September.
The latest Series A2 round was led by Tencent and joined by LAV; SoftBank’s China-based arm SBCVC, Chinese
alternative asset manager CDH Investments; and healthcare-focused investment firm Sherpa Healthcare Partners.
Singleron will invest the proceeds to develop single-cell sequencing techniques and products, and also to ramp up its
international presence.
With headquarters in Nanjing and offices in Suzhou, US, and Germany, Singleron uses single-cell analysis
techniques to conduct clinical diagnosis, drug development, and health management. Its early-stage investors also
include China Growth Capital, Arch Venture Partners, Frees Fund, and Oriza Seed.
South Africa Today
Read more at VolaNews
